These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12972536)

  • 1. Bevacizumab, bleeding, thrombosis, and warfarin.
    Kilickap S; Abali H; Celik I
    J Clin Oncol; 2003 Sep; 21(18):3542; author reply 3543. PubMed ID: 12972536
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of metastatic colorectal cancer with monoclonal antibody to vascular endothelial growth factor: does the metastatic site make the difference?
    Graziano F; Cascinu S
    J Clin Oncol; 2003 Sep; 21(18):3542-3; author reply 3543. PubMed ID: 12972535
    [No Abstract]   [Full Text] [Related]  

  • 3. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
    Miller KD
    Clin Breast Cancer; 2003 Feb; 3(6):421-2. PubMed ID: 12636887
    [No Abstract]   [Full Text] [Related]  

  • 4. [Future trends in anticancer chemotherapy].
    Kudoh S; Yamauchi S
    Nihon Rinsho; 2002 May; 60 Suppl 5():726-32. PubMed ID: 12101772
    [No Abstract]   [Full Text] [Related]  

  • 5. Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):85-8. PubMed ID: 12952562
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiangiogenesis drug promising for metastatic colorectal cancer.
    McCarthy M
    Lancet; 2003 Jun; 361(9373):1959. PubMed ID: 12801743
    [No Abstract]   [Full Text] [Related]  

  • 7. [Paclitaxel].
    Hino M; Kudo S
    Nihon Rinsho; 2002 May; 60 Suppl 5():343-8. PubMed ID: 12101685
    [No Abstract]   [Full Text] [Related]  

  • 8. [Strategy of therapy for lung cancer].
    Kishi Y; Saijo N
    Nihon Rinsho; 2002 May; 60 Suppl 5():305-8. PubMed ID: 12101678
    [No Abstract]   [Full Text] [Related]  

  • 9. Managing patients treated with bevacizumab combination therapy.
    Gordon MS; Cunningham D
    Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [[Last news from ASCO 2000 in the topic of colorectal cancer] ].
    Sobrero A
    Tumori; 2000; 86(3):A1-2. PubMed ID: 10939611
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab for advanced colorectal cancer.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in older patients and patients with poorer performance status.
    Hoff PM
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S19-25. PubMed ID: 17145521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Hochster HS
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S8-14. PubMed ID: 17145525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab proves active in wide range of cancers.
    Oncology (Williston Park); 2004 Aug; 18(9):1158, 1199. PubMed ID: 15471199
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab plus fluorouracil: the value of being part of a developing story.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2005 Jun; 23(16):3660-2. PubMed ID: 15738545
    [No Abstract]   [Full Text] [Related]  

  • 19. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 20. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Wolff RA; Fuchs M; Di Bartolomeo M; Hossain AM; Stoffregen C; Nicol S; Heinemann V
    Cancer; 2012 Sep; 118(17):4132-8. PubMed ID: 22213153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.